PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces today that it has again won first prize for the most innovative technology at a highly-focussed gathering of industry and academic drug discovery experts.
PharmaDiagnostics won the ELRIG Technology Prize at Drug Discovery 2010 Coventry, in September 2010 for the SoPRano technology platform. This is the second time in a row SoPRano has received industry acclaim at an ELRIG event. The company also won first prize at ELRIG’s Liquid Handling & Label Free Technologies show held in the UK earlier this year. The ELRIG Technology Prize is awarded at each ELRIG show for the best technology on show. It is voted for by the delegates, in a free-vote made via their feedback forms.
ELRIG (European Laboratory Robotics Interest Group) is a not for profit organization whose primary purpose is to provide a communication forum for users and vendors within the scientific research, development or production community (industrial and academic) with the aim of increasing their awareness of automation techniques and products used for scientific research, development or production.
Label-free screening is an area of great interest and potential growth in pharmaceutical research. To date, the expanding SPR segment of this market has been dominated by providers of expensive specialist instrumentation that is unable, due to technical constraints, to provide the through-put required for routine adoption of label-free screening. PharmaDiagnostics’ SoPRano label-free platform is the first SPR-based system to utilize standard plate-readers, and simple assay protocols. This makes for increased accessibility for researchers, lowers barrier to adoption and also offers excellent scalability, thus lowering costs, as it is not necessary to increase instrument expenditure to increase throughput.
“Winning this prize for the second time in a row shows that SoPRano’s appeal to knowledgeable industry and academic experts is real and ongoing,” said Dr David Ricketts, CEO at PharmaDiagnostics. “SoPRano was chosen from a large range of technologies/vendors, including label-free instrument providers, many of whom have well established technologies. Our two successive wins demonstrate the high level of market interest and market demand for a label-free platform that requires no expensive instrumentation, and offers high throughput – truly the next generation in label-free screening.”
“The ELRIG Technology Prize has become a much coveted prize at ELRIG organized conferences, as the vote is entirely composed by delegates who are from a broad span of the industry including senior representatives,” said Dermot Boylan, ELRIG’s General Manager. “Delegates are often confronted with a wide range of differing technologies at the show. To win the prize, you need to impress a variety of delegates with differing interests. To win the prize for the second time in a row is as yet unparalleled.”
PharmaDiagnostics NV
